Five things to know:
1. The FDA approved Biogen’s Alzheimer’s drug, aducanumab, branded under the name Aduhelm, on June 7. It is the first approval the agency has granted to an Alzheimer’s treatment since 2003.
2. Biogen and its development partner Eisai estimate that the drug, given as an infusion, will cost $4,312 per infusion for a patient, or $56,000 a year.
3. Cigna is entering a value-based contract with Biogen for the drug, under which the companies will track patient outcomes and performance, Biogen and Eisai said June 7.
4. Additionally, Biogen and Eisai are working with CVS Health on cognitive screenings, which will begin in September in 14 large cities.
5. Medicare is expected to cover the drug, though out-of-pocket maximums will determine how much beneficiaries may need to pay for the treatment.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
